The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

EGRX FINANCIAL STATEMENTS

Eagle Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

EGRXEagle Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
0100 M200 M300 M2020202120222023

Profit Funnel

Q2 2023 · TTM
Revenue257.6 M $Gross Profit179.9 M $ · 70%Operating Income23.7 M $ · 9%Pre-tax Income32.8 M $ · 13%Net Income to Owners15.6 M $ · 6%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue257.6 M $-5.4%
Gross Profit179.9 M $-10.2%
Operating Income23.7 M $-59.0%
EBITDA57 M $+6.2%
Net Income to Owners15.6 M $-31.7%

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 M400 M2020202120222023

Capital Structure

Q2 2023
Total Assets404.8 M
  • Equity252 M $62%
  • Current Liabilities86.6 M $21%
  • Long-term Liabilities66.2 M $16%

Key Figures

YoY change
Total Assets404.8 M $+6.0%
Total Liabilities152.8 M $+6.3%
Total Equity252 M $+5.9%
Cash & ST Investments15.4 M $-58.0%
Total Debt71.6 M $+33.6%
Net Debt56.3 M $+230.3%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
020 M40 M60 M2020202120222023

Cash Flow Bridge

Q2 2023 · TTM
-30 M-20 M-10 M0-9.3 M $Operating-23.8 M $Investing11.9 M $Financing-21.2 M $Net Change

Key Figures

YoY change
Operating Cash Flow-9.3 M $-126.2%
Capital Expenditures84 K $-62.2%
Free Cash Flow-9.4 M $-126.6%
Dividends Paid247 K $-86.6%

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on EGRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.